NEOS Investment Management LLC Has $2.11 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

NEOS Investment Management LLC boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 26.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 48,239 shares of the company’s stock after buying an additional 10,157 shares during the period. NEOS Investment Management LLC’s holdings in Revolution Medicines were worth $2,110,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Citigroup Inc. lifted its position in Revolution Medicines by 29.5% in the 3rd quarter. Citigroup Inc. now owns 117,938 shares of the company’s stock worth $5,348,000 after buying an additional 26,871 shares in the last quarter. FMR LLC raised its holdings in shares of Revolution Medicines by 4.4% during the third quarter. FMR LLC now owns 5,875,893 shares of the company’s stock worth $266,472,000 after acquiring an additional 250,037 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of Revolution Medicines by 44.4% during the third quarter. Walleye Capital LLC now owns 323,732 shares of the company’s stock worth $14,681,000 after acquiring an additional 99,589 shares in the last quarter. Captrust Financial Advisors grew its stake in Revolution Medicines by 4.1% in the third quarter. Captrust Financial Advisors now owns 8,459 shares of the company’s stock valued at $384,000 after purchasing an additional 337 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in Revolution Medicines in the 3rd quarter worth about $645,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RVMD has been the subject of several recent research reports. Guggenheim boosted their price target on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. UBS Group boosted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. JPMorgan Chase & Co. increased their target price on shares of Revolution Medicines from $63.00 to $71.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 3rd. Finally, HC Wainwright boosted their price target on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, March 3rd. Twelve investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Revolution Medicines currently has an average rating of “Buy” and a consensus price target of $66.31.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares in the company, valued at $4,489,834.24. The trade was a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares of the company’s stock, valued at approximately $17,238,658.56. This represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is currently owned by company insiders.

Revolution Medicines Stock Down 2.0 %

RVMD opened at $37.35 on Friday. The stock’s 50 day moving average price is $40.32 and its two-hundred day moving average price is $45.56. The firm has a market capitalization of $6.94 billion, a P/E ratio of -10.40 and a beta of 1.46. Revolution Medicines, Inc. has a 12-month low of $29.55 and a 12-month high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). As a group, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.